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Abstract—Synaptic degeneration is central in Alzheimer’s disease (AD) pathogenesis and biomarkers to monitor
this pathophysiology in living patients are warranted. We developed a novel sandwich enzyme-linked immunosor-
bent assay (ELISA) for the measurement of the pre-synaptic protein SNAP-25 in cerebrospinal ﬂuid (CSF) and
evaluated it as a biomarker for AD. CSF samples included a pilot study consisting of AD (N= 26) and controls
(N= 26), and two independent clinical cohorts of AD patients and controls. Cohort I included CSF samples from
patients with dementia due to AD (N= 17), patients with mild cognitive impairment (MCI) due to AD (N= 5) and
controls (N= 17), and cohort II CSF samples from patients with dementia due to AD (N= 24), patients with MCI
due to AD (N= 18) and controls (N= 36). CSF levels of SNAP-25 were signiﬁcantly increased in patients with AD
compared with controls (P  0.00001). In both clinical cohorts, CSF levels of SNAP-25 were signiﬁcantly increased
in patients with MCI due to AD (P< 0.0001). SNAP-25 could diﬀerentiate dementia due to AD (N= 41) from con-
trols (N= 52) and MCI due to AD (N= 23) from controls (N= 52) with areas under the curve of 0.967 (P< 0.0001)
and 0.948 (P< 0.0001), respectively. CSF SNAP-25 is a promising AD biomarker that diﬀerentiates AD patients in
diﬀerent clinical stages of the disease from controls with excellent diagnostic accuracy. Future studies should
address the speciﬁcity of the CSF SNAP-25 against common diﬀerential diagnoses to AD, as well as how the bio-
marker changes in response to treatment with disease-modifying drug candidates.
This article is part of a Special Issue entitled: SNARE proteins.  2018 The Authors. Published by Elsevier Ltd on behalf of
IBRO. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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accumulation of aggregated amyloid b, intra-cellular24
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neuroscience.2018.11.038neuroﬁbrillary tangles, synaptic degeneration and
neuronal degeneration (Blennow et al., 2006). Several
cerebrospinal ﬂuid (CSF) biomarkers for Alzheimer’s dis-
ease are accessible, including total tau (T-tau) and phos-
phorylated tau protein (P-tau), mirroring tau pathology
and neurodegeneration, respectively, and amyloid-b1–42
(Ab1–42), mirroring aggregation of the peptide into plaques
(Blennow et al., 2010; Olsson et al., 2016). Numerous
studies have consistently shown a reduction in Ab1–42
attended by a marked increase in CSF T-tau and P-tau
in Alzheimer’s disease, and also in the mild cognitive
impairment (MCI) stage of the disease (Blennow et al.,
2010; Olsson et al., 2016), while there not yet is a con-
ventional CSF biomarker for synaptic dysfunction. Synap-
tic degeneration of the most vulnerable brain regions is an
early key characteristic of Alzheimer’s disease (Davies/licenses/by/4.0/).
luid SNAP-25 in Patients with Alzheimer’s Disease. Neuroscience (2018), https://doi.org/10.1016/j.
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10 December 2018et al., 1987; Masliah et al., 2001; Scheﬀ et al., 2007). Ear-
lier post-mortem studies suggested that synaptic dysfunc-
tion in Alzheimer’s disease is related to cognitive decline
(DeKosky and Scheﬀ, 1990; Blennow et al., 1996) and
that synaptic loss occurs early in the disease (Davies
et al., 1987; Masliah et al., 2001), with disturbances in
presynaptic terminals (Masliah et al., 1991) and reduc-
tions in synaptic protein levels (DeKosky and Scheﬀ,
1990; Blennow et al., 1996). Thus, it is evident that reli-
able CSF biomarkers to monitor synaptic dysfunction
and degeneration directly in Alzheimer’s disease patients
would be very useful.
In recent years, there are promising results for some
synaptic biomarkers in CSF, including the pre-synaptic
proteins synaptosomal-associated protein 25 (SNAP-25)
(Brinkmalm et al., 2014a; b) and synaptotagmin (Ohrfelt
et al., 2016), as well as the post-synaptic protein neuro-
granin (Kvartsberg et al., 2015a,b; Sanﬁlippo et al.,
2016; Wellington et al., 2016). A marked increase of these
synaptic CSF markers were found in dementia due to Alz-
heimer’s disease and already in MCI due to Alzheimer’s
disease (Brinkmalm et al., 2014a,b; Kvartsberg et al.,
2015a,b; Ohrfelt et al., 2016; Sanﬁlippo et al., 2016;
Wellington et al., 2016), with higher CSF levels correlating
with more marked future cognitive decline among MCI
patients (Kvartsberg et al., 2015a,b).
The pre-synaptic protein SNAP-25 is one of the major
proteins involved in the formation of the SNARE (soluble
N-ethylmaleimide-sensitive factor attachment protein
receptor) complexes (Sollner et al., 1993a; Sollner
et al., 1993b; Jahn et al., 2003). This protein assembly
is a crucial step in neurotransmitter release and modiﬁca-
tions of any of the SNARE proteins could alter the appo-
sition of them, which could inﬂuence calcium-dependent
exocytosis of neuro-transmitters (Sollner et al., 1993a;
Sollner et al., 1993b; Jahn et al., 2003; Sudhof 2004).
The central function of SNAP-25 in the regulation of
neuro-transmitter release along with the recently sug-
gested post-synaptic impact on receptor traﬃcking, spine
morphogenesis and plasticity (Antonucci et al., 2013;
Antonucci et al., 2016), makes it as a potential biomarker
candidate reﬂecting synaptic dysfunction and degenera-
tion in Alzheimer’s disease. We have previously shown
that a N-terminal fragment of SNAP-25 is a promising bio-
marker by utilizing an approach of aﬃnity puriﬁcation and
mass spectrometry (Brinkmalm et al., 2014a,b), and up to
now, no enzyme-linked immunosorbent assay (ELISA) for
assessment of SNAP-25 in CSF samples has been avail-
able. One advantage of the ELISA technology is the ease
with which it can be performed in a high-through-put for-
mat. The feasibility and the accessibility that the ELISA
oﬀers would be required in future studies for assessment
of synaptic proteins in large patient cohorts.
In this study, we report a novel ELISA for
measurements of the pre-synaptic protein SNAP-25 in
CSF. The utility of the novel SNAP-25 ELISA was
initially veriﬁed in brain tissue extracts and from patients
with Alzheimer’s disease and age-matched controls,
followed by a pilot study of CSF samples. Then, CSF
SNAP-25 was assessed in two independent clinical
cohorts, with the main ﬁnding being markedly higher150
Please cite this article in press as: O¨hrfelt A et al. A Novel ELISA for the Measurement of Cerebrospinal F
neuroscience.2018.11.038levels in patients with MCI due to Alzheimer’s disease
and dementia due to Alzheimer’s disease.
EXPERIMENTAL PROCEDURES
Human brain tissue samples
All brain tissues, from the superior parietal gyrus, were
obtained from the Netherlands Brain Bank. The clinical
and demographic characteristics autopsy-conﬁrmed
patients with Alzheimer’s disease (N= 15) and age-
matched controls (N= 15) have previously been
published (Brinkmalm et al., 2014a,b). In our study, all
Alzheimer’s disease patients fulﬁlled Braak stages 5 or
6, i.e. late stages of disease, while the controls fulﬁlled
Braak stages 0 or 1 (Braak and Braak, 1991). The brain
extraction procedure was performed as described by
Brinkmalm et al. (2014a,b). In the present study, brain
homogenates from the Tris fractions (soluble proteins)
were analyzed.
Quality control (QC) CSF samples
The repeatability of the novel SNAP-25 ELISA was
examined on decoded CSF samples supplied by the
clinical routine section at the Clinical Neurochemistry
Laboratory, The Sahlgrenska University Hospital,
Mo¨lndal, Sweden. The procedure making pools of left-
over CSF aliquots were approved by the Ethics
Committee at University of Gothenburg. The quality
control CSF pool 1 (QC1 sample) had an Ab1–42 of
446 ng/L, a T-tau level of 332 ng/L and a P-tau level of
46 ng/L. The QC2 sample had an Ab1–42 level of 405 ng/
L, a T-tau level below 561 ng/L and a P-tau level of
50 ng/L.
CSF samples in the pilot study
An initial pilot study was performed using de-identiﬁed
CSF samples supplied by the Clinical Neurochemistry
Laboratory, Sahlgrenska University, Mo¨lndal, following
procedures approved by the Ethics Committee at
University of Gothenburg. Patients were designated as
control or Alzheimer’s disease according to CSF
Alzheimer’s disease core biomarker levels using in-
house optimized cut-oﬀ levels for Alzheimer’s disease
(Hansson et al., 2006): Ab1–42 <550 ng/L, T-tau
>400 ng/L, and P-tau >50 ng/L. The subjects were older
than 55 years. The age-matched test material included 26
patients with an Alzheimer’s disease biomarker proﬁle
and 26 subjects with a control biomarker proﬁle (Fig. 2).
CSF samples in the clinical studies
In this study, SNAP-25 levels in CSF were measured in
two independent clinical patient cohorts. The clinical and
demographic characteristics have been reported
previously (Ohrfelt et al., 2016). To facilitate for the reader
essential parts used for diagnosing the patients and
selecting the CSF are brieﬂy given below (Ohrfelt et al.,
2016). At the Center of Cognitive at Lariboisie`re
Fernand-Widal University Hospital APHP, patients under-
went a thorough clinical examination involving personalluid SNAP-25 in Patients with Alzheimer’s Disease. Neuroscience (2018), https://doi.org/10.1016/j.
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10 December 2018medical and family histories, neurological examination,
neuropsychological assessment, lumbar puncture with
CSF biomarker analysis, and a brain structural imaging
study with MRI. The diagnosis for each patient was made
by neurologists considering CSF results and according to
validated clinical diagnostic criteria for dementia due to
Alzheimer’s disease (McKhann et al., 2011), MCI due to
Alzheimer’s disease (Albert et al., 2011; Dubois et al.,
2014), subjective cognitive impairment (Sperling et al.,
2011), psychiatric disorder (DSM-IV). The CSF samples
of the study were selected after a second validation step
by a neurologist (CP) and a biochemist (EAB). Patients
were not included in the study, without a consensus diag-
nosis or in case of disagreement about the ﬁnal diagnosis.
This procedure resulted in selection of CSF samples from
subject with MCI due to Alzheimer’s disease, dementia
due to Alzheimer’s disease, and neurological controls
(no neurodegenerative disorders). The Alzheimer’s dis-
ease core CSF biomarkers have been included in the
research criteria for the diagnosis of both early and man-
ifest Alzheimer’s disease by the International Working
Group (Dubois et al., 2014) and in the diagnostic guideli-
nes from the National Institute on Aging-Alzheimer’s
Association (McKhann et al., 2011), respectively. The fol-
lowing cut-oﬀ values were used to deﬁne a biochemical
Alzheimer’s disease signature as supportive criteria for
dementia due to Alzheimer’s disease (McKhann et al.,
2011): Ab1–42 (<550 ng/L), T-tau (>400 ng/L), and P-
tau (>50 ng/L). CSF was obtained by lumbar puncture
between the L3/L4 or L4/L5 intervertebral space, and
samples were immediately centrifuged at 1800g for
10 min at +4 C, and stored at 80 C pending analysis.234
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The demographic characteristics and the biomarker CSF
levels of the Alzheimer’s disease core biomarkers for the
cohorts have been reported previously (Ohrfelt et al.,
2016). Brieﬂy, cohort I consisted of ﬁve patients with
MCI due to Alzheimer’s disease (one man and four
women, 62–88 years), 17 patients with dementia due to
Alzheimer’s disease (ﬁve men and 12 women,
52–86 years), and 17 neurological controls (seven men
and ten women, 41–82 years) (Ohrfelt et al., 2016). The
replication sample set (cohort II) consisted of 18 patients
with MCI due to Alzheimer’s disease (ﬁve men and 13
women, 58–83 years), 24 patients with dementia due to
Alzheimer’s disease (seven men and 17 females,
52–84 years) and 36 neurological controls (13 men and
23 women, 43–80 years) (Ohrfelt et al., 2016). In cohort
I, the patients with MCI due to Alzheimer’s disease were
older than the controls. Both patients with MCI due to
Alzheimer’s disease and dementia due to Alzheimer’s dis-
ease were slightly but signiﬁcantly older than the controls
in cohort II (Ohrfelt et al., 2016).257
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263Analysis of CSF biomarkers
Ab1–42, T-tau, and tau phosphorylated at threonine 181
(P-tau) protein measurements were performed using
commercially available assays from Fujirebio
(INNOTEST b-AMYLOID(1–42), INNOTEST hTAU AgPlease cite this article in press as: O¨hrfelt A et al. A Novel ELISA for the Measurement of Cerebrospinal F
neuroscience.2018.11.038and INNOTEST PHOSPHO-TAU(181P) according to
the manufacturer’s instructions.Synthetic peptides of SNAP-25 and antibodies
The synthetic peptide of N-terminal acetylated SNAP-25
(Ac-2-47 SNAP-25) was bought from CASLO Aps
(Lyngby, Denmark). The monoclonal mouse antibody
clone 71.1 recognizing the N-terminal portion of SNAP-
25 (aa 20–40) was purchased from Synaptic Systems
(Go¨ttingen, Germany). Polyclonal chicken IgY antibody
was produced by immunization with Ac-2-47 SNAP-25
and the subsequent antigen aﬃnity puriﬁcation of the
total IgY extract was conducted by Getica AB
(Gothenburg, Sweden). Biotinylation of the Ac-2-47
SNAP-25 puriﬁed chicken IgY antibody was performed
accordingly to the manual, Simoa Homebrew Detector
Biotinylation Protocol, provided by Quanterix (Lexington,
MA, USA). A ratio of biotin to antibody of 40:1 was
applied.A novel sandwich ELISA method for SNAP-25
F16 Maxisorp Loose Nunc-Immuno plates (Thermo
Fisher Scientiﬁc Nunc A/S, Roskilde, Denmark) were
coated with 100 mL of monoclonal mouse antibody clone
71.1 (1 g/L) diluted 1:400 in 50 mM carbonate buﬀer, pH
9.6 and incubated over night or up to three nights at
+2–8 C. The plates were washed with 385 mL of
phosphate-buﬀered saline PBS-Tween20 (0.05%) (PBS-
T). The same washing procedure was repeated
between every following incubation step. After the
coating and washing steps, the plates were blocked with
300 mL Roti-Block (Carl Roth, Germany) diluted 1:10 in
PBS-T for one hour at room temperature. All standards
and samples were analyzed in duplicate. The standards
of Ac-2-47 SNAP-25 were diluted in assay buﬀer, i.e.
Roti-Block diluted 1:100 in PBS-T, to providing a ﬁnal
concentration range of 4000–62.5 ng/L or 1000–7.8 ng/L
for brain samples and CSF samples, respectively. Brain
tissue homogenates were diluted 1:15 in assay buﬀer,
while neat CSF samples were added to the plates.
Samples and standards (50 mL) were incubated over
night at +2–8 C, simultaneously with 50 mL biotinylated
aﬃnity Ac-2-47 SNAP-25 puriﬁed chicken IgY antibody
(1 g/L) diluted 1:500 in assay buﬀer. Enhanced
Streptavidin-HRP conjugate (0.01 g/L) (Kem-En-Tec
Diagnostics, Taastrup, Denmark), pre-diluted 1:100 in
Uni-Stabil Plus (Kem-En-Tec Diagnostics) (stored at
+2–8 C pending analysis), was then diluted 1:200 in
assay buﬀer, and was incubated for 30 min at room
temperature. Then, 100 mL TMB ONETM, ready-to-use
substrate (KE-MEN-TEC Diagnostics) were added. The
reaction was quenched with 100 mL of H2SO4 (0.2 M).
The absorbance was measured at 450 nm. The
concentrations of SNAP-25 in samples were calculated
from the four parameter standard curve. For each brain
sample a ratio was calculated where the SNAP-25 level
was divided with the total protein concentration.luid SNAP-25 in Patients with Alzheimer’s Disease. Neuroscience (2018), https://doi.org/10.1016/j.
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
Fig. 1. SNAP-25 in brain tissue in Alzheimer’s disease (AD) and
controls. The ﬁgure shows the individual values SNAP-25 (displayed
as the ratio SNAP-25/total protein) in the soluble protein fraction in
the superior parietal gyrus from controls (green) and patients with AD
(violet). The lower, upper and middle lines of the error bars
correspond to the 25th and 75th percentiles and medians,
respectively.
Fig. 2. Individual values for SNAP-25 (A) and demographic data
including Alzheimer’s disease (AD) core biomarker levels (B) from the
pilot study for the patients with AD (violet) and controls (green) based
on the biomarker proﬁle. The lower, upper and middle lines of the
error bars correspond to the 25th and 75th percentiles and medians,
respectively (A).
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The within-day precision (repeatability) and the between-
day repeatability (intermediate precision) were
determined using two QC samples (QC1 and QC2)
analyzing them at three diﬀerent days (N= 5 or N= 6).
Lower limit of quantiﬁcation (LLOQ) was calculated
according to Andreasson et al. (2015).
Statistical analysis
Because most of the analytes were not normally
distributed (Shapiro-Wilk test, P< 0.05), non-parametric
statistics were used for analysis. Data are given as
median (inter-quartile range). Diﬀerences between more
than two groups were assessed with Kruskal–Wallis
test. Statistically signiﬁcant results (P< 0.05) were
followed by Mann–Whitney U-tests to investigate group
diﬀerences. Receiver operating characteristic (ROC)
curves were performed on each subject group on the
levels of SNAP-25 in order to assess its diagnostic
value. The area under the curve (AUC) and a 95%
conﬁdence interval (CI) was calculated for SNAP-25
using GraphPad Prism 7.02. The correlation coeﬃcients
(rho) were calculated using the Spearman two-tailed
correlation test. SPSS 24 was employed for most of the
statistical analyzes.
RESULTS
Assay performance
The novel ELISA is directed against the N-terminal of
SNAP-25, that measure both partially degraded N-
terminal SNAP-25 fragments as well as the possible full-
length protein. Within-day repeatability was 9.6% for QC
sample 1 and 15% for QC sample 2. Between-day
repeatability was 13% (QC1) and 16% (QC2). The
repeatability was within acceptable ranges, i.e. within-
day 15 and between-day 20 (Lee and Hall (2009)).
LLOQ was 15.7 ng/L.
Human brain and the pilot CSF study
Initially, we tested the novel SNAP-25 ELISA on brain
tissue homogenates from age-matched patients with
Alzheimer’s disease and controls. We found that SNAP-
25 levels were signiﬁcantly decreased in patients with
later stages of Alzheimer’s disease compared with the
controls (Fig. 1). In the pilot CSF study, the levels of
SNAP-25 were signiﬁcantly increased in the group with
an Alzheimer’s disease biomarker proﬁle (N= 26) than
in the group with a control biomarker proﬁle (N= 26)
(Fig. 2).
CSF SNAP-25 in the clinical cohorts
CSF levels of the SNAP-25 were signiﬁcantly higher in
patients with MCI due to Alzheimer’s disease (cohort I,
II and all samples), and in dementia due to Alzheimer’s
disease compared with controls (cohort I, II and all
samples) (Fig. 3). SNAP-25 could diﬀerentiate MCI due
to Alzheimer’s disease from controls in both cohorts and
in the entire set of samples, with AUCs (conﬁdencePlease cite this article in press as: O¨hrfelt A et al. A Novel ELISA for the Measurement of Cerebrospinal F
neuroscience.2018.11.038interval (CI)) of 1 (1-1) (P= 0.001) (cohort I), 0.975
(0.943–1.008) (P< 0.0001) (cohort II) and 0.948
(0.964–1.004) (P< 0.0001) (all samples) (Fig. 4A, C).
SNAP-25 could also diﬀerentiate dementia due to
Alzheimer’s disease from controls with AUCs (CI) of
0.982 (0.946–1.017) (P< 0.0001) (cohort I), 0.970
(0.935–1.005) (P< 0.0001) (cohort II) and 0.967
(0.938–0.996) (P< 0.0001) (all samples) (Fig. 4B, C).luid SNAP-25 in Patients with Alzheimer’s Disease. Neuroscience (2018), https://doi.org/10.1016/j.
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Fig. 3. Individual values for SNAP-25 in CSF samples within cohort I (A), cohort II (B) and for the
entire set of samples (C) from subjects with dementia due to Alzheimer’s disease (AD) (violet), mild
cognitive impairment due to Alzheimer’s disease (MCI-AD) (orange) and control (green) individuals.
The lower, upper and middle lines of the error bars correspond to the 25th and 75th percentiles and
medians, respectively.
Fig. 4. ROC curve analysis for SNAP-25 in CSF for diﬀerentiation of MCI due to Alzheimer’s disease
(MCI-AD) from controls in cohort I (violet), cohort II (green) and in the entire set of samples (black) (A).
ROC curve analysis for SNAP-25 in CSF for diﬀerentiation of dementia due to Alzheimer’s disease
(AD) from controls in cohort I (violet), cohort II (green) and in the entire set of samples (black) (B). The
area under the curve (95% conﬁdence interval) is shown in the included table (C).
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10 December 2018There was a correlation between the CSF levels of
SNAP-25 and the age in patients with dementia due to
Alzheimer’s disease (cohort I), while there were no
statistically signiﬁcant correlations between SNAP-25
and age in any other of the investigated groupsPlease cite this article in press as: O¨hrfelt A et al. A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheim
neuroscience.2018.11.038(Table 1). There were no
statistically signiﬁcant correlations
between CSF SNAP-25 and mini-
mental state examination (MMSE)
scores in any group.
The CSF levels of SNAP-25
correlated with the levels of T-tau
and P-tau in both the control
group and in patients with
dementia due to Alzheimer’s
disease (Table 1). Additionally,
the CSF levels of SNAP-25
correlated with the levels of T-tau
and P-tau in patients with MCI
due to Alzheimer’s disease within
the entire set of samples, but only
with the levels of P-tau within
cohort II (Table 1). SNAP-25
correlated positively with Ab1–42 in
the control group of cohort II and
for the entire set of samples,
while there were no correlations
within other investigated groups
(Table 1).
DISCUSSION
We developed a novel ELISA for
assessment of the pre-synaptic
protein SNAP-25 in CSF samples.
In one pilot study and both
investigated clinical cohorts, we
found that the CSF levels of
SNAP-25 were signiﬁcantly higher
in patients with dementia due to
Alzheimer’s disease than in
controls. There was also a
consistent increase in early
disease (i.e. MCI due to
Alzheimer’s disease) as
compared to controls.
Synaptic dysfunction and
degeneration predict cognitive
decline in Alzheimer’s disease
(Davies et al., 1987; Masliah
et al., 2001). The pre-synaptic pro-
tein SNAP-25 is one of the promi-
nent proteins involved in the
regulation of synaptic transmission
(Sollner et al., 1993a,b; Sudhof,
2004), and therefore could possi-
bly be a biomarker candidate that
mirrors synaptic degeneration and
dysfunction in Alzheimer’s dis-
ease. We found that the CSF
levels of SNAP-25 were consis-
tently elevated in patients withdementia due to Alzheimer’s disease compared with con-
trols in two separate clinical cohorts, as well as in a group
having an Alzheimer’s disease biomarker proﬁle com-
pared to a group with a control biomarker proﬁle. Addition-er’s Disease. Neuroscience (2018), https://doi.org/10.1016/j.
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
Table 1. Correlation between cerebrospinal ﬂuid SNAP-25, age, MMSE and biomarker levels for the diagnostic groups in the clinical cohortsa
SNAP-25 SNAP-25 SNAP-25
Cohort I Control (N = 17) MCI-AD (N = 18) AD (N = 17)
Age N.S. rho = 0.503, P = 0.04
MMSE N.S. N.S.
Amyloid-b1–42 N.S. N.S.
Total tau rho = 0.805, P= 0.0002 rho = 0.738, P= 0.001
Phosphorylated tau rho = 0.715, P= 0.002 rho = 0.830, P= 0.00004
Cohort II Control (N = 36) MCI-AD (N = 18) AD (N = 24)
Age N.S. N.S. N.S.
MMSE N.S. N.S. N.S.
Amyloid-b1–42 rho = 0.363, P= 0.03 N.S. N.S.
Total tau rho = 0.743, P< 0.00001 N.S. rho = 0.663, P= 0.0004
Phosphorylated tau rho = 0.618, P= 0.00008 rho = 0.513, P= 0.03 rho = 0.604, P= 0.002
All samples Control (N = 53) MCI-AD (N = 23) AD (N = 41)
Age N.S. N.S. N.S.
MMSE N.S. N.S. N.S.
Amyloid-b1–42 rho = 0.325, P= 0.02 N.S. N.S.
Total tau rho = 0.744, P< 0.00001 rho = 0.453, P= 0.03 rho = 0.726, P< 0.00001
Phosphorylated tau rho = 0.639, P< 0.00001 rho = 0.637, P= 0.001 rho = 0.736, P< 0.00001
a Correlations presented by the Spearman’s rank correlation coeﬃcient (rho). Non-signiﬁcant (N.S., P> 0.05) correlations were not reported.
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10 December 2018ally, the level of SNAP-25 was increased already in the
MCI stage of Alzheimer’s disease, supporting the notion
that this pre-synaptic protein might be an early marker
for Alzheimer’s disease (Brinkmalm et al., 2014a,b).
There is evidence suggesting that pre-synaptic dysfunc-
tion may occur early in the pathogenesis of dementia
(Masliah et al., 2001), and that compensatory post-
synaptic alterations may occur in response to pre-
synaptic discrepancies (DeKosky and Scheﬀ, 1990).
These results are altogether in agreement with our earlier
studies of the synaptic proteins SNAP-25 (Brinkmalm
et al., 2014a; b), synaptotagmin (Ohrfelt et al., 2016)
and neurogranin (Kvartsberg et al., 2015a,b).
We present a sensitive ELISA, which showed
reproducibility and intermediate precision not exceeding
%CV of 15 and 16, respectively. SNAP-25 exists in two
isoforms in the brain, SNAP-25A and SNAP-25B (Bark
and Wilson, 1994). These isoforms diﬀer only in nine
alternate amino acids 58, 60. 65, 69, 79, 84 and 88–89,
which are located beyond the potential cleavage site of
SNAP-25, all of which can be measured using the novel
ELISA. The design of the novel ELISA is based on our
previous ﬁnding of numerous N-terminally acetylated sol-
uble SNAP-25 fragments in both human brain tissue and
CSF from subjects with Alzheimer’s disease and controls
(Brinkmalm et al., 2014a,b). In the previous study, we
applied aﬃnity puriﬁcation (immunoprecipitation) against
the N-terminal of SNAP-25 and mass spectrometry ana-
lyzed for subsequently quantiﬁcation of tryptic peptides
in CSF (Brinkmalm et al., 2014a,b). The most prominent
result was that the tryptic peptide furthest away from the
targeted N-terminal provided the best diﬀerential diagnos-
tic biomarker of Alzheimer’s disease (Brinkmalm et al.,
2014a,b), which might correspond to a truncated SNAP-
25 fragment ending after amino acid 47 (Ac-2–47)
(Brinkmalm et al., 2014a,b). In the present study, we con-
ﬁrm that CSF SNAP-25 can discriminate both patientsPlease cite this article in press as: O¨hrfelt A et al. A Novel ELISA for the Measurement of Cerebrospinal F
neuroscience.2018.11.038with dementia due to Alzheimer’s disease and patients
with MCI due to Alzheimer’s disease from controls with
high diagnostic accuracy in ROC curve analyzes
(Brinkmalm et al., 2014a,b). In agreement, we also found
that the CSF levels of SNAP-25 were signiﬁcantly ele-
vated in Alzheimer’s disease (Brinkmalm et al., 2014a,
b). The novel ELISA does not exclusively target the Ac-
2-47, and possibly longer N-terminal forms of SNAP-25
might also be analyzed. Interestingly, truncated N-
terminal fragments of SNAP-25 might be created by cal-
pain cleavage (Ando et al., 2005; Grumelli et al., 2008),
and the activity of calpain is increased in Alzheimer’s dis-
ease brain (Kurbatskaya et al., 2016). The cleavage of
SNAP-25 by calpain might regulate synaptic transmission
by suppressing the neuro-transmitter release (Ando et al.,
2005).
In agreement with the majority of previous reports
summarized by Honer (2003), we found that the SNAP-
25 levels in brain were signiﬁcantly decreased in later
stages of Alzheimer’s disease compared with the controls
(Gabriel et al., 1997; Mukaetova-Ladinska et al., 2000;
Brinkmalm et al., 2014a,b). The lower levels of SNAP-
25 might reﬂect the synaptic degeneration known to occur
in disease-aﬀected regions of the brain in Alzheimer’s dis-
ease (DeKosky and Scheﬀ, 1990). Intra-cellular SNAP-25
is anchored to the pre-synaptic membrane by palmitoyla-
tion of a central cysteine-rich region (amino acids 85, 88,
90 and 92) (Veit et al., 1996). Since the palmitoylation is a
reversible reaction, SNAP-25 could possibly reside free in
the pre-synaptic cytoplasm. However, the mechanism of
liberation of SNAP-25 into CSF and what it reﬂects are
unknown. Herein, we found that SNAP-25 correlated with
the levels of T-tau and P-tau in both the control group and
in patients with dementia due to Alzheimer’s disease in all
examined sample sets. CSF T-tau has previously been
suggested to be a general marker of damage to cortical
non-myelinated neurons (Blennow et al., 2010). In con-luid SNAP-25 in Patients with Alzheimer’s Disease. Neuroscience (2018), https://doi.org/10.1016/j.
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10 December 2018trast, P-tau might be a more speciﬁc marker for Alzhei-
mer’s disease (Blennow et al., 2010), since high CSF
levels of P-tau have been found to correlate to the accu-
mulation of cortical neuroﬁbrillary tangles (Buerger
et al., 2006; Tapiola et al., 2009). Altogether, these ﬁnd-
ings suggest that SNAP-25 is a sensitive Alzheimer’s dis-
ease biomarker that to some extent mirrors general
neurodegeneration, which is in agreement with our ﬁrst
pilot study (Brinkmalm et al., 2014a,b). The result that
the levels of SNAP-25 correlated well with T-tau and P-
tau, imply that SNAP-25 might be a valuable surrogate
biomarker in future clinical treatment studies with tau-
based- modifying drugs (Panza et al., 2016).
Marked synaptic degeneration and loss are the main
pathological features of Alzheimer’s disease that
correlate with cognitive decline. Since SNAP-25 is
directly involved in the maintenance of synaptic function
(Sollner et al., 1993a,b; Sudhof, 2004), CSF SNAP-25
could be a potential biomarker to follow progression of
clinical symptoms. In the present study, there were no
correlations between the MMSE score, i.e., the severity
of cognitive impairment, and SNAP-25 in any of the exam-
ined groups Although we did not found correlation
between cognition and SNAP-25, previous studies sup-
port that SNAP-25 single nucleotide polymorphisms are
associated with cognitive decline (Gosso et al., 2008;
Guerini et al., 2014). Further studies using a larger set
of clinical samples are warranted to investigate if SNAP-
25 in CSF could be used for assessment of future rate
of cognitive decline. The relationship of CSF SNAP-25
with neuroimaging markers (positron emission tomogra-
phy and magnetic resonance imaging) would also be
important to evaluate. For instance, changes in glucose
utilization identiﬁed with ﬂuorodeoxyglucose positron
emission tomography could possible reﬂect neurodegen-
eration/synaptic dysfunction (Petrie et al., 2009), and
the cortical glucose metabolism would therefore be inter-
esting to study together with CSF SNAP-25.
The strengths of our study are that we present a novel
ELISA for assessment of the CSF levels of SNAP-25 and
that consistent ﬁndings were shown in one pilot set and
two independent replication cohorts of CSF samples.
One drawback is the cross-sectional design that
complicates the investigation of possible association
between CSF SNAP-25 and synaptic degeneration over
time.
In summary, we present a novel ELISA for
measurement of the pre-synaptic protein SNAP-25 in
CSF samples. CSF SNAP-25 levels were increased in
patients with MCI due to Alzheimer’s disease and
dementia due to Alzheimer’s disease compared with
controls, which are in agreement with our previous
ﬁndings, and supports the notion that SNAP-25 could be
a valuable biomarker both in early Alzheimer’s disease
and in manifest Alzheimer’s disease dementia. Future
studies should examine the ability to monitor cognitive
decline, the speciﬁcity of the biomarker against non-
Alzheimer’s disease dementias, as well as how it
changes in response to treatment with novel disease-
modifying drug candidates.Please cite this article in press as: O¨hrfelt A et al. A Novel ELISA for the Measurement of Cerebrospinal F
neuroscience.2018.11.038DECLARATIONS
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